Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

CAR-Multicenter Analysis (CAR-MA): Retrospektiv studie för att karakterisera CAR T-cellsutfall och relaterade toxiciteter hos barn och unga vuxna med B-ALL

23 oktober 2026 uppdaterad av: National Cancer Institute (NCI)

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.

To evaluate the response of extramedullary disease following CAR T-cell therapy.

To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.

Studieöversikt

Detaljerad beskrivning

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

  • To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

  • To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
  • To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
  • To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
  • To evaluate the response of extramedullary disease following CAR T-cell therapy.
  • To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
  • To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
  • To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
  • To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
  • To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Studietyp

Observationell

Inskrivning (Faktisk)

57

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Maryland
      • Bethesda, Maryland, Förenta staterna, 20892
        • National Cancer Institute (NCI)

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

3 år till 25 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.

Beskrivning

  • Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: RETROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
1

Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Response free survival (completed)
Tidsram: 6 months

To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab.

6 months
Outcome evaluation
Tidsram: 12 months

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Complete Response Rate (completed)
Tidsram: 12 months

To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Relapse Rate (completed)
Tidsram: 12 months

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Response free survival (completed)
Tidsram: 12 months

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Minimal Residual Disease detection (completed)
Tidsram: 12 months

To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Impact of immunotherapies on CAR outcomes
Tidsram: 12 months

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes

12 months
Cytopenias after CAR
Tidsram: 12 months

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes

12 months
Response of extramedullary disease
Tidsram: 12 months

To evlauate the response of extramedullary disease following CAR T cell therapy

12 months
Frequency of malignant neoplasms
Tidsram: 12 months

To evaluate the response of extramedullary disease following CAR T cell therapy

12 months
Response, survival and toxicities in subpopulations
Tidsram: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

12 months
Impact of next generation sequencing MRD and duration of B cell aplasia
Tidsram: 12 months

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

12 months
Frequency of infections
Tidsram: 12 months

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

12 months
Response, survival and toxicities after CAR
Tidsram: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy)

12 months
Compare toxicities and outcomes across CAR constructs
Tidsram: 12 months

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.)

12 months
Impact of CAR on other health-related outcomes
Tidsram: 12 months

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes

12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Sara K Silbert, M.D., National Cancer Institute (NCI)

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 oktober 2021

Primärt slutförande (Faktisk)

29 oktober 2024

Avslutad studie (Faktisk)

29 oktober 2024

Studieregistreringsdatum

Först inskickad

29 juni 2022

Först inskickad som uppfyllde QC-kriterierna

29 juni 2022

Första postat (Faktisk)

30 juni 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

26 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 oktober 2026

Senast verifierad

22 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All IPD recorded in the medical record will be shared with intramural investigators upon request.

Tidsram för IPD-delning

Clinical data available during the study and indefinitely.

Kriterier för IPD Sharing Access

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera